Dr. Jia-You Fang

Position：Professor	Laboratory：Pharmaceutics Laboratory
Degree：Ph. D	Graduated from：Kaohsiung Medical University
Phone：+886-3-2118800 ext. 5521	E-MAIL：fajy@mail.cgu.edu.tw

Research Interests:

1. Pharmaceutics
2. Drug targeting
3. Cosmetic science
4. Nanomedicine

The selected publications from total 335 articles

*, corresponding author

1. Nirmal, G.R., Lin, Z.C., Lin, C.H., Sung, C.T., Liao, C.C., Fang, J.Y.* (2022) Polydopamine/IR820 nanoparticles as topical phototheranostics for inhibiting psoriasiform lesions through dual photothermal and photodynamic treatments. Biomater. Sci., in press.
2. Lee, W.R., Chou, W.L., Lin, Z.C., Sung, C.T., Lin, C.Y., Fang, J.Y.* (2022) Laser-assisted nanocarrier delivery to achieve cutaneous siRNA targeting for attenuating psoriasiform dermatitis. J. Control. Release, 347, 590–606.
3. Tseng, C.H., Lin, C.F., Aljuffali, I.A., Huang, J.R., Yang, S.H., Fang, J.Y.* (2022) The effectiveness of synthetic methoxylated isoflavones in delivering to the skin and alleviating psoriasiform lesions via topical absorption. Int. J. Pharm., 617, 121629.

4. Lee, W.R., Hsiao, C.Y., Chang, Z.Y., Wang, P.W., Aljuffali, I.A., Lin, J.Y., Fang, J.Y.* (2022) Cutaneous delivery of cosmeceutical peptides enhanced by picosecond- and nanosecond-domain Nd:YAG lasers with quick recovery of the skin barrier function: comparison with microsecond-domain ablative lasers. Pharmaceutics, 14, 450.
5. Fang, J.Y., Huang, T.H., Chen, W.J., Aljuffali, I.A., Hsu, C.Y. (2022) Rhubarb hydroxyanthraquinones act as antiobesity agents to inhibit adipogenesis and enhance lipolysis. Biomed. Pharmacother., 146, 112497.
6. Fang, J.Y., Chou, W.L., Lin, C.F., Sung, C.T., Alalaiwe, A., Yang, S.C. (2021) Facile biofilm penetration of cationic liposomes loaded with DNase I/proteinase K to eradicate *Cutibacterium acnes* biofilm for treating cutaneous and catheter infections. Int. J. Nanomed., 16, 8121–8138.
7. Chuang, S.Y., Chen, C.Y., Yang, S.C., Alalaiwe, A., Lin, C.H., Fang, J.Y.* (2021) 2,4-Dimethoxy-6-methylbenzene-1,3-diol, a benzenoid from *Antrodia cinnamomea*, mitigates psoriasiform inflammation by suppressing MAPK/NF-κB phosphorylation and GDAP1L1/Drp1 translocation. Front. Immunol., 12, 664425.
8. Nirmal, G.R., Lin, Z.C., Tsai, M.J., Yang, S.C., Alalaiwe, A., Fang, J.Y.* (2021) Photothermal treatment by PLGA-gold nanorod-isatin nanocomplexes under near-infrared irradiation for alleviating psoriasiform hyperproliferation. J. Control. Release, 333, 487–499.
9. Lin, Z.C., Hwang, T.L., Huang, T.H., Tahara, K., Trousil, J., Fang, J.Y.* (2021) Monovalent antibody-conjugated lipid-polymer nanohybrids for active targeting to desmoglein 3 of keratinocytes to attenuate psoriasiform inflammation. Theranostics, 11, 4567–4584.
10. Liao, C.C., Yu, H.P., Yang, S.C., Alalaiwe, A., Dai, Y.S., Liu, F.C., Fang, J.Y.* (2021) Multifunctional lipid-based nanocarriers with antibacterial and anti-inflammatory activities for treating MRSA bacteremia in mice. J. Nanobiotechnol., 19, 48.
11. Elzoghby, A.O., Abdelmoneem, M.A., Hassanin, I.A., Abd Elwakil, M.M., Elnaggar, M.A., Mokhtar, S., Fang, J.Y., Elkhodairy, K.A. (2020) Lactoferrin, a multi-functional glycoprotein: Active therapeutic, drug nanocarrier and targeting ligand. Biomaterials, 263, 120355.
12. Tang, K.W., Lin, Z.C., Wang, P.W., Alalaiwe, A., Tseng, C.H., Fang, J.Y.* (2020) Facile skin targeting of a thalidomide analog containing benzyl chloride moiety alleviates experimental psoriasis via the suppression of MAPK/NF-κB/AP-1 phosphorylation in keratinocytes. J. Dermatol. Sci., 99, 90–99.
13. Alalaiwe, A., Lin, Y.K., Lin, C.H., Wang, P.W., Lin, J.Y., Fang, J.Y.* (2020) The absorption of polycyclic aromatic hydrocarbons into the skin to elicit cutaneous inflammation: the establishment of structure–permeation and in silico–in vitro–in vivo relationships. Chemosphere, 255, 126955.
14. Yu, H.P., Liu, F.C., Lin, C.Y., Umoro, A., Trousil, J., Hwang, T.L., Fang, J.Y.* (2020) Suppression of neutrophilic inflammation can be modulated by the droplet size of anti-inflammatory nanoemulsions. Nanomedicine, 15, 773–791.
15. Wu, C.Y.J., Chen, C.H., Lin, C.Y., Feng, L.Y., Lin, Y.C., Wei, K.C., Huang, C.Y., Fang, J.Y.*, Chen, P.Y. (2020) CCL5 of glioma-associated microglia/macrophages regulates glioma migration and

invasion via calcium-dependent matrix metalloproteinase-2. Neuro-Oncology, 22, 253–266.

16. Yu, H.P., Liu, F.C., Umoro, A., Lin, Z.C., Elzoghby, A.O., Hwang, T.L., Fang, J.Y.* (2020) Oleic acid-based nanosystems for mitigating acute respiratory distress syndrome in mice through neutrophil suppression: how the particulate size affects therapeutic efficiency. J. Nanobiotechnol., 18, 25.
17. Lee, W.R., Lin, Y.K., Alalaiwe, A., Wang, P.W., Liu, P.Y., Fang, J.Y.* (2020) Fractional laser-mediated siRNA delivery for mitigating psoriasis-like lesions via IL-6 silencing. Mol. Ther.-Nucl. Acids, 19, 240–251.
18. Chen, P.Y., Wu, C.Y.J., Fang, J.H., Chen, H.C., Feng, L.Y., Huang, C.Y., Wei, K.C., Fang, J.Y.*, Lin, C.Y. (2019) Functionl change of effector tumor-infiltrating $CCR5^{+}CD38^{+}HLA\text{-}DR^{+}CD8^{+}$ T cells in glioma microenvironment. Front. Immunol., 10, 2395.
19. Weng, J.R., Huang, T.H., Lin, Z.C., Alalaiwe, A., Fang, J.Y.* (2019) Cutaneous delivery of [1-(4-chloro-3-nitrobenzenesulfonyl)-1*H*-indol-3-yl]-methanol, an indole-3-carbinol derivative, mitigates psoriasiform lesion by blocking MAPK/NF-κB/AP-1 activation. Biomed. Pharmacother., 119, 109398.
20. Hsiao, C.Y., Yang, S.C., Alalaiwe, A., Fang, J.Y.* (2019) Laser ablation and topical drug delivery: a review of recent advances. Expert Opin. Drug Deliv., 16, 937–952.
21. Lin, C.Y., Hsu, C.Y., Elzoghby, A.O., Alalaiwe, A., Hwang, T.L., Fang, J.Y.* (2019) Oleic acid as the active agent and lipid matrix in cilomilast-loaded nanocarriers to assist PDE4 inhibition of activated neutrophils for mitigating psoriasis-like lesions. Acta Biomater., 90, 350–361.
22. Fang, J.Y., Lin, C.H., Huang, T.H., Chuang, S.Y. (2019) In vivo rodent models of type 2 diabetes and their usefulness for evaluating flavonoid bioactivity. Nutrients, 11, 530.
23. Lin, Z.C., Hsieh, P.W., Hwang, T.L., Chen, C.Y., Sung, C.T., Fang, J.Y.* (2018) Topical application of anthranilate derivatives ameliorates psoriatic inflammation in a mouse model by inhibiting keratinocyte-derived chemokine expression and neutrophil infiltration. FASEB J., 32, 6783–6795.
24. Abdelmoneem, M.A., Mahmoud, M., Zaky, A., Helmy, M.W., Sallam, M., Fang, J.Y.*, Elkhodairy, K.A., Elzoghby, A.O. (2018) Dual-targeted casein micelles as green nanomedicine for synergistic phytotherapy of hepatocellular carcinoma. J. Control. Release, 287, 78–93.
25. Elgohary, M.M., Helmy, M.W., Abdelfattah, E.Z.A., Ragab, D.M., Mortada, S.M., Fang, J.Y.*, Elzoghby, A.O. (2018) Targeting sialic acid residues on lung cancer cells by inhalable boronic acid-decorated albumin nanocomposites for combined chemo/herbal therapy. J. Control. Release, 285, 230–243.
26. Chuang, S.Y., Lin, C.H., Sung, C.T., Fang, J.Y.* (2018) Murine models of psoriasis and their usefulness for drug discovery. Expert Opin. Drug Discov., 13, 551–562.
27. Liu, F.C., Yu, H.P., Lin, C.Y., Elzoghby, A.O., Hwang, T.L., Fang, J.Y.* (2018) Use of cilomilast-loaded phosphatiosomes to suppress neutrophilic inflammation for attenuating acute lung injury: the effect of nanovesicular surface charge. J. Nanobiotechnol., 16, 35.
28. Hsu, C.Y., Sung, C.T., Aljuffali, I.A., Chen, C.H., Hu, K.Y., Fang, J.Y.* (2018) Intravenous anti-MRSA

phosphatiosomes mediate enhanced affinity to pulmonary surfactants for effective treatment of infectious pneumonia. Nanomed.-Nanotechnol. Biol. Med., 14, 215-225.

29. Liu, K.S., Huang, T.H., Aljuffali, I.A., Chen, E.L., Wang, J.J., Fang, J.Y.* (2017) Exploring the structure-permeation relationship of topical tricyclic antidepressants used for skin analgesia. Int. J. Pharm., 523, 386–397.
30. Hsieh, P.W., Hung, C.F., Lin, C.H., Huang, C.W., Fang, J.Y.* (2017) Anti-melasma codrug of retinoic acid assists cutaneous absorption with attenuated skin irritation. Eur. J. Pharm. Biopharm., 114, 154–163.

Patents:

1. Fluorescent dye compositions and uses thereof, Chia-Yu Fang, Chih-Jen Wen, US9,855,346 B2, 美國, 2014/11/06-2034/11/06
2. 使用 2,4-二甲氧基-6-甲基苯-1,3-二醇來治療異位性皮膚炎，王東弘、方嘉佑、楊世駿、黃澤宏，I670055，中華民國 2019/9/1-2038/4/10
3. 使用 2,4-二甲氧基-6-甲基苯-1,3-二醇來防止和/或抑制葡萄球菌屬物種的生長以及生物膜形成，王東弘、方嘉佑、楊世駿、黃澤宏，I680756，中華民國 2020/1/1-2038/7/1
4. 使用 2,4-二甲氧基-6-甲基苯-1,3-二醇來預防和/或治療乾癬，王東弘、方嘉佑、楊世駿、莊士億、黃澤宏，I716940，中華民國 2021/1/21-2039/7/22
5. 凝膠型防曬組成物，吳智元、楊世駿、王東弘、方嘉佑，I760745，中華民國 2022/4/11-2040/5/11


HAPPY